阿达曼坦 - 奎诺沙混合体:在急性髓性白血病中精确化学类型及其分子机制
Sangita Dattatray Shinde1, Ambika Chamoli2, Sai Swetha Uppalapati2
1Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research (NIPER)─Ahmedabad, Palaj, Gandhinagar 382355 Gujarat, India.
Journal of medicinal chemistry
|March 31, 2025
概括
一种新型的昆素-阿达曼坦化合物选择性地准具有t(8;21) 遗传异常的急性髓性白血病 (AML). 这种精密治疗抑制了癌细胞的生长,并诱导了癌细胞的死亡,节省了健康细胞,并为改善患者的结果提供了希望.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药用化学 医学化学
背景情况:
- 急性髓性白血病 (AML) 是一种具有不良预后的侵袭性血液性恶性瘤.
- 染色体转位是AML的特定亚型,但目前的治疗缺乏特异性.
- 标准化疗对t(8;21) AML是非特异性的,导致对健康细胞的毒性,并限制有效性.
研究的目的:
- 开发一种针对急性髓性白血病 (AML) 的向治疗方法,该治疗方法具有t(8;21) 染色体异常.
- 为了研究一种用于精密治疗的新型昆素绑定阿达曼坦化学型.
- 在临床前模型中评估该化合物的选择性和作用机制.
主要方法:
- 使用一种无金属和无光的合成协议,制造了诺素-阿达曼坦化合物.
- 生物测试用于评估细胞增殖和诱导细胞死亡.
- RNA测序和蛋白质组分析阐明了该化合物对细胞通路的影响.
主要成果:
- 这种新型化合物选择性地抑制了AML细胞的增殖和诱导细胞死亡.
- 观察到关键生长和代谢途径的破坏.
- 该化合物表现出特异性,不影响其他白血病和固体癌症细胞系.
结论:
- 一种精确的化学型,针对t(8;21) AML已经成功开发.
- 这种有针对性的方法提供了一个潜在的治疗策略,降低了毒性.
- 需要进一步的研究,以推动这种化合物在AML患者的临床应用.
相关概念视频
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Drugs that Destabilize Microtubules
1.9K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
1.9K


